Market LIVE
Published markets; coverage varies by country
Product profile · United States

EPINEPHRINE

 ·  Patent Litigation & Settlement History ↓

IngredientEPINEPHRINE
Application typeNDA
Application205029
Product005
Dosage formSOLUTION
RouteINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Strength1MG/ML (1MG/ML)
Approval date2024-03-04
Marketing statusPrescription
Status event—
ApplicantBPI LABS
Product source

Current GenericRadar decision

Year2026
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2026-05-29
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2026-05-29
Status event—

Final ANDA existence confirmed. 2026-05-29 is earliest verified date, not fully confirmed absolute earliest. ANDA219239 product003 date unresolved; do not copy application ORIG date. Target year 2026 uses verified evidence and is subject to correction. AG and tentative excluded.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
219239 / 003APPLICATION_FINAL_OBSERVATION · FINAL_PRODUCT_DATE_UNVERIFIED——GLANDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
220562 / 001FINAL_APPROVAL · FINAL_APPROVED2026-05-29—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217426 / 001FINAL_APPROVAL · FINAL_APPROVED2026-07-31—DEVA HOLDING ANONIM SIRKETINEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 2 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
220562 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2026-05-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217426 / 001DEVA HOLDING ANONIM SIRKETIFINAL_APPROVAL · FINAL_APPROVED2026-07-31 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2026-05-29TERMINAL_GENERIC_BASISFinal ANDA existence confirmed. 2026-05-29 is earliest verified date, not fully confirmed absolute earliest. ANDA219239 product003 date unresolved; do not copy application ORIG date. Target year 2026 uses verified evidence and is subject to correction. AG and tentative excluded.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.